REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

Core Insights - REGENXBIO Inc. announced the presentation of interim data from the Phase II ALTITUDE trial for surabgene lomparvovec (ABBV-RGX-314) targeting diabetic retinopathy at the American Academy of Ophthalmology 2025 Annual Meeting [1][2] - Surabgene lomparvovec is a one-time gene therapy developed in collaboration with AbbVie, aimed at treating wet age-related macular degeneration and diabetic retinopathy [1][2] Company Overview - REGENXBIO is a biotechnology company focused on gene therapy, founded in 2009, and has developed a late-stage pipeline for various diseases, including RGX-202 for Duchenne and RGX-121 for MPS II [3] - The company utilizes the NAV AAV8 vector in surabgene lomparvovec, which encodes an antibody fragment to inhibit vascular endothelial growth factor (VEGF), a key factor in the development of leaky blood vessels in the retina [2][3]